Introduction
Metaiodobenzylguanidine (MIBG), which can be labeled with either 131 I or 123 I, mimics the neurotransmitter norepinephrine and specifically targets malignant cells of the sympathetic nervous system [1, 2] . Since 131 I-MIBG was reported to visualize tumors of the adrenal medulla in the early 1980s [3, 4] , 131 I-MIBG and 123 I-MIBG have been widely used for detecting lesions in patients with malignant neuroendocrine tumors, such as malignant pheochromocytomas, malignant paragangliomas, medullary thyroid carcinomas, carcinoid tumors and neuroblastomas [5] [6] [7] [8] [9] . 123 I-MIBG has superiority over 131 I-MIBG with diagnostic use, because the γ-ray energy of 123 I (159keV) befits the image quality and lesion detectability for scintigraphy compared with that of 131 I (364keV) [10] [11] [12] . Moreover, 123 I offers favorable dosimetry compared to 131 I, because of their γ-ray energy and their half-life ( 123 I: 13.13 hours, 131 I: 8.04 days) [13] .
It has been reported that other imaging modalities may be useful in detecting nuroendocrine tumors. Many articles compared 123 I-MIBG with 18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) positron emission tomography (PET) or 18 F-FDG PET/computed tomography (CT) have been reported. These articles did not show good concordance [14] [15] [16] [17] hours from the beginning of 131 I-MIBG administration. All patients were treated in the isolation room until radiation decreased to less than 30µSv/hr at 1m. All therapies were well tolerated. A whole body scan with therapeutic dose of 131 I-MIBG was obtained once at 2 to 5 days (mean = 3.4 days) after injection with 15cm/min of scanning speed on a photo peak of 364keV with a 15% window, using a high energy collimator. Table 1 
